Biocept Inc (NASDAQ:BIOC)
| 4.55 BATS BZX Real-Time Price As of 11:24am ET |  +0.035 / +0.78%Today’s Change | 2.11 Today|||52-Week Range 13.00 | +59.09% Year-to-Date |
| SECTOR Health Services | INDUSTRY Medical/Nursing Services | MARKET CAP $61.5M |
Company Description
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.
Contact Information
Biocept, Inc. 5810 Nancy Ridge Drive San Diego California 92121-2840 |
Employees
Shareholders
| Mutual fund holders | 6.16% |
| Other institutional | 2.02% |
| Individual stakeholders | -- |
Top Executives
| Michael W. Nall | President, Chief Executive Officer & Director |
| Timothy C. Kennedy | CFO, Senior VP-Operations & Secretary |
| Pavel Tsinberg | Director-Technology Development |
| Lyle J. Arnold | Chief Scientific Officer & Senior Vice President |
| Veena M. Singh | Senior Medical Director |
